EMEA-000310-PIP03-10-M03

Key facts

Active substance
ocrelizumab
Therapeutic area
Neurology
Decision number
P/0028/2019
PIP number
EMEA-000310-PIP03-10-M03
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of multiple sclerosis
Route(s) of administration
Intravenous use
Contact for public enquiries
Roche Registration GmbH

Tel.  +41 616879411
E-mail: info.paediatrics@roche.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating